Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has a diagnosis of Major Depressive Disorder that has been present for at least a 4-week period as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)~Exclusion Criteria:~* Participant has a history of suicide attempt~* Participant has a history of treatment-resistant depression, defined as persistent depressive symptoms despite treatment with adequate doses of antidepressants from two different classes for an adequate amount of time~* Participant has active psychosis~* Participant has a medical history of seizures~* Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part A: SAGE-217 (Type: EXPERIMENTAL): Participants received SAGE-217, 30 milligrams (mg), oral solution, once daily for 14 days, as tolerated.
- Part B: Placebo (Type: PLACEBO_COMPARATOR): Eligible participants received matching placebo capsules once daily for 14 days.
- Part B: SAGE-217 (Type: EXPERIMENTAL): Eligible participants received SAGE-217, 30 mg, oral capsules, once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).